Back to Journals » Cancer Management and Research » Volume 13

Peripheral Blood Markers Associated with Immune-Related Adverse Effects in Patients Who Had Advanced Non-Small Cell Lung Cancer Treated with PD-1 Inhibitors

Authors Liu W, Liu Y, Ma F, Sun B, Wang Y, Luo J, Liu M, Luo Z

Received 24 November 2020

Accepted for publication 13 January 2021

Published 27 January 2021 Volume 2021:13 Pages 765—771

DOI https://doi.org/10.2147/CMAR.S293200

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 3

Editor who approved publication: Dr Eileen O'Reilly


Wenhui Liu,1,2 Yiping Liu,1,2 Fang Ma,3 Bao Sun,1,2 Ying Wang,1,2 Jianquan Luo,1,2 Mouze Liu,1,2 Zhiying Luo1,2

1Department of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha, People’s Republic of China; 2Institute of Clinical Pharmacy, Central South University, Changsha, People’s Republic of China; 3Department of Oncology, The Second Xiangya Hospital, Central South University, Changsha, People’s Republic of China

Correspondence: Zhiying Luo No. 139, People’s Middle Street, Furong District, Changsha City, Hunan Province 40013, People’s Republic of China
Tel +86 13787034276
Fax +86 0731 85294099
Email lzhy199089@csu.edu.cn

Background: Immune checkpoint inhibitors (ICIs) have transformed the treatment landscape for patients with advanced non-small-cell lung cancer (aNSCLC), but immune-related adverse events (irAEs) have been evidenced curtailed the clinical use of them.
Purpose: The aim of this study was to research the influences of inflammation-related peripheral blood markers, including neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) levels, on anti-PD-1 inhibitor-induced irAEs.
Patients and Methods: A retrospective analysis was conducted of patients treated with PD-1 inhibitors for stage III–IV NSCLC at a single center from 2017 to 2020 were included. Clinical characteristics, peripheral blood markers at the baseline and before subsequent treatment cycles were collected. NLR and PLR were calculated by division of neutrophil and platelet by lymphocyte measured in peripheral blood. The development of irAEs was evaluated and monitored from the therapy start based on CTCAE V4.03.
Results: A total of 150 patients were included. Fifty-seven patients had occurred at least one irAEs during follow-up, and mainly grade 1– 2 (73.68%). Pruritus, rash and thyroiditis were the most commonly irAEs. Low NLR, PLR and neutrophil at baseline were significantly associated with the development of severe irAEs (P-values were 0.023, 0.0016 and 0.009). The levels of neutrophil, NLR and PLR also significantly decreased when occurred irAEs compared with baseline (P-values were 0.0069, 0.017 and 1.18E-5, respectively).
Conclusion: The levels of NLR, PLR and neutrophil were associated with the increased risk of severe irAEs when baseline levels were low. NLR, PLR, and neutrophil are simple and available biomarkers that can be used to help predict severe adverse effects in NSCLC patients treated with anti-PD-1 inhibitors.

Keywords: immune checkpoint inhibitors, NSCLC, irAE, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]